Boots pre-close
This article was originally published in The Rose Sheet
Executive Summary
Boots Healthcare International second half sales jump about 13% at comparable exchange rates, UK company reports March 27 in a fiscal 2003 (ending March 31) 1pre-close statement. Clearasil sales continue to improve in response to increased marketing support and launches of new product lines, Boots states. Firm currently is rolling out Clearasil Total Control, a non-acne skin care line expected to generate $32 mil. in first year U.S. sales (2"The Rose Sheet" Dec. 16, 2002, p. 3). As part of company's increasing focus on core businesses, Boots the Chemists and Boots Healthcare International, Boots will exit Pure Beauty concept, which currently consists of six stores in the UK, firm says...
You may also be interested in...
Clearasil Launch Aims For Broader Control Of U.S. Skin Care Category
Boots Healthcare International is launching Clearasil Total Control, a non-acne treatment skin care range, to fill a void in the mass market for products that offer basic skin care benefits to young women, the company said during a press event in New York City Dec. 10
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.